HAS2 and neoplasm: Notably, 4-MU was reported as a hyaluronic acid synthase inhibitor in previous studies, which significantly reduced the synthesis of hyaluronic acid (HA) in the ECM by inhibiting the expression of HAS2/3, thereby interfering with HA-dependent tumor microenvironment construction and fibrosis progression [57–59].